ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,475.09
      0.27%
      US Tech 100
      19,202.00
      -0.39%
      Dow Jones
      39,169.52
      0.13%
      Brent Oil
      86.805
      0.32%
      Bitcoin
      62,600.94
      -0.40%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Rubius Therapeutics Inc (RUBY)

      7. Rubius Therapeutics Inc (RUBY) News

      RUBY

      Rubius Therapeutics (RUBY)

      Rubius Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RUBY
      DateTimeSourceHeadlineSymbolCompany
      08/09/20228:00AMGlobeNewswire Inc.Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:RUBYRubius Therapeutics Inc
      07/26/20228:00AMGlobeNewswire Inc.Rubius Therapeutics to Announce Second Quarter 2022 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
      07/19/20225:54PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:RUBYRubius Therapeutics Inc
      07/19/20227:00AMPR Newswire (US)HotSpot Therapeutics Appoints Jose Carmona to Board of DirectorsNASDAQ:RUBYRubius Therapeutics Inc
      07/14/20228:08AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      07/14/20228:00AMGlobeNewswire Inc.Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of DirectorsNASDAQ:RUBYRubius Therapeutics Inc
      06/24/202211:03AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RUBYRubius Therapeutics Inc
      06/22/20228:00AMGlobeNewswire Inc.Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual MeetingNASDAQ:RUBYRubius Therapeutics Inc
      06/22/20226:03AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:RUBYRubius Therapeutics Inc
      06/08/20224:10PMEdgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:RUBYRubius Therapeutics Inc
      06/08/20224:08PMEdgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:RUBYRubius Therapeutics Inc
      06/01/20228:00AMGlobeNewswire Inc.Rubius Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:RUBYRubius Therapeutics Inc
      05/26/20225:00PMGlobeNewswire Inc.Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual MeetingNASDAQ:RUBYRubius Therapeutics Inc
      05/24/20228:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      05/24/20228:00AMGlobeNewswire Inc.Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of DirectorsNASDAQ:RUBYRubius Therapeutics Inc
      05/13/20224:44PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/13/20224:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/13/20224:35PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/13/20224:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/13/20224:30PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/13/20228:31AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      05/11/20226:27AMTipRanksH.C. Wainwright Remains a Buy on Rubius Therapeutics (RUBY)NASDAQ:RUBYRubius Therapeutics Inc
      05/10/202212:38PMTipRanksRubius Therapeutics (RUBY) Gets a Hold Rating from SVB SecuritiesNASDAQ:RUBYRubius Therapeutics Inc
      05/10/20228:46AMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:RUBYRubius Therapeutics Inc
      05/10/20228:31AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RUBYRubius Therapeutics Inc
      05/10/20228:16AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      05/10/20228:00AMGlobeNewswire Inc.Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:RUBYRubius Therapeutics Inc
      04/26/20228:00AMGlobeNewswire Inc.Rubius Therapeutics to Announce First Quarter 2022 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
      04/22/20226:08PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      04/11/20228:40AMTipRanksAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Genfit SA (GNFT) and Rubius Therapeutics (RUBY)NASDAQ:RUBYRubius Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:RUBY